ATE322283T1 - Transdermale verwendung von sekretin zur behandlung von autismus - Google Patents
Transdermale verwendung von sekretin zur behandlung von autismusInfo
- Publication number
- ATE322283T1 ATE322283T1 AT99927416T AT99927416T ATE322283T1 AT E322283 T1 ATE322283 T1 AT E322283T1 AT 99927416 T AT99927416 T AT 99927416T AT 99927416 T AT99927416 T AT 99927416T AT E322283 T1 ATE322283 T1 AT E322283T1
- Authority
- AT
- Austria
- Prior art keywords
- secretin
- ferring
- compositions
- dmso
- effective amount
- Prior art date
Links
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 abstract 11
- 102100037505 Secretin Human genes 0.000 abstract 8
- 108010086019 Secretin Proteins 0.000 abstract 8
- 229960002101 secretin Drugs 0.000 abstract 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 abstract 6
- 239000000203 mixture Substances 0.000 abstract 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 2
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- -1 Secretin-Ferring Chemical compound 0.000 abstract 1
- 239000000443 aerosol Substances 0.000 abstract 1
- 230000003542 behavioural effect Effects 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 239000000969 carrier Substances 0.000 abstract 1
- 239000000499 gel Substances 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 239000006210 lotion Substances 0.000 abstract 1
- 239000007937 lozenge Substances 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 230000037368 penetrate the skin Effects 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 239000000829 suppository Substances 0.000 abstract 1
- 239000003826 tablet Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2235—Secretins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/38—Pediatrics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8857598P | 1998-06-09 | 1998-06-09 | |
| US09/229,208 US6197746B1 (en) | 1998-05-19 | 1999-01-13 | Method of using secretin for treating autism |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE322283T1 true ATE322283T1 (de) | 2006-04-15 |
Family
ID=26778819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99927416T ATE322283T1 (de) | 1998-06-09 | 1999-06-09 | Transdermale verwendung von sekretin zur behandlung von autismus |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US6197746B1 (de) |
| EP (1) | EP1085901B1 (de) |
| JP (1) | JP2002517467A (de) |
| AT (1) | ATE322283T1 (de) |
| AU (1) | AU772911B2 (de) |
| CA (1) | CA2333657A1 (de) |
| DE (1) | DE69930739D1 (de) |
| WO (1) | WO1999064059A2 (de) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6197746B1 (en) * | 1998-05-19 | 2001-03-06 | Repligen Corporation | Method of using secretin for treating autism |
| US6020310A (en) * | 1997-05-19 | 2000-02-01 | Repligen Corporation | Method for assisting in differential diagnosis and treatment of autistic syndromes |
| US6020314A (en) * | 1998-08-11 | 2000-02-01 | Milkhaus Laboratory, Inc. | Methods for treatment of neurological disorders |
| AU1779301A (en) * | 1999-11-22 | 2001-06-04 | Joseph A. Rogoff | Secretin and secretin pharmaceuticals for treating attention deficit disorder |
| US6632429B1 (en) | 1999-12-17 | 2003-10-14 | Joan M. Fallon | Methods for treating pervasive development disorders |
| US6534063B1 (en) | 1999-12-17 | 2003-03-18 | Joan M. Fallon | Methods for treating pervasive development disorders |
| GB0008326D0 (en) * | 2000-04-06 | 2000-05-24 | Shs International Ltd | Diagnosis and treatment of autism and related disorders |
| GB0016441D0 (en) | 2000-07-04 | 2000-08-23 | Pharmagene Lab Limited | Therapeutic method |
| US20070053895A1 (en) * | 2000-08-14 | 2007-03-08 | Fallon Joan M | Method of treating and diagnosing parkinsons disease and related dysautonomic disorders |
| US6660831B2 (en) * | 2000-08-14 | 2003-12-09 | Joan M. Fallon | Method for diagnosing and treating dysautonomia and other dysautonomic conditions |
| EP1486205B1 (de) * | 2000-08-25 | 2007-10-17 | Research Corporation Technologies, Inc | Verwendung von antikonvulsiven Aminosäure zur Behandlung von Migräne |
| US8030002B2 (en) | 2000-11-16 | 2011-10-04 | Curemark Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
| GB0118383D0 (en) * | 2001-07-27 | 2001-09-19 | Pharmagene Lab Ltd | Therapeutic methods |
| US6585996B1 (en) | 2002-03-13 | 2003-07-01 | Westlake Laboratories, Inc. | Lipid-soluble thiamine derivatives in the treatment of autism |
| US8100844B2 (en) * | 2002-04-25 | 2012-01-24 | Ultraflex Systems, Inc. | Ambulating ankle and knee joints with bidirectional dampening and assistance using elastomeric restraint |
| EP1605960A2 (de) * | 2003-03-12 | 2005-12-21 | Repligen Corporation | Verwendung von sekretin und sekretin-analoga zur behandlung von affektiven störungen |
| US20070154534A1 (en) * | 2003-03-12 | 2007-07-05 | Sheitman Brian B | Use of secretin in the treatment of schizophrenia |
| WO2004100899A2 (en) * | 2003-05-13 | 2004-11-25 | The Mclean Hospital Corporation | Use of secretin in treatments of disorders associated with the amygdala |
| US7947285B2 (en) * | 2003-12-12 | 2011-05-24 | Fein Seymour H | Methods for preventing post endoscopic retrograde cholangiopancreatography pancreatitis |
| US7381698B2 (en) * | 2003-12-12 | 2008-06-03 | Chirhoclin, Inc. | Methods for treatment of acute pancreatitis |
| US20060198838A1 (en) * | 2004-09-28 | 2006-09-07 | Fallon Joan M | Combination enzyme for cystic fibrosis |
| GB0504096D0 (en) * | 2005-02-28 | 2005-04-06 | Tipogen As | Method |
| US20070034214A1 (en) * | 2005-08-12 | 2007-02-15 | Dochniak Michael J | Method to affect the development of autism spectrum disorders |
| US20080058282A1 (en) | 2005-08-30 | 2008-03-06 | Fallon Joan M | Use of lactulose in the treatment of autism |
| US20070116695A1 (en) * | 2005-09-21 | 2007-05-24 | Fallon Joan M | Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders |
| US8658163B2 (en) | 2008-03-13 | 2014-02-25 | Curemark Llc | Compositions and use thereof for treating symptoms of preeclampsia |
| US8084025B2 (en) * | 2008-04-18 | 2011-12-27 | Curemark Llc | Method for the treatment of the symptoms of drug and alcohol addiction |
| US9320780B2 (en) | 2008-06-26 | 2016-04-26 | Curemark Llc | Methods and compositions for the treatment of symptoms of Williams Syndrome |
| US20090324730A1 (en) * | 2008-06-26 | 2009-12-31 | Fallon Joan M | Methods and compositions for the treatment of symptoms of complex regional pain syndrome |
| US11016104B2 (en) * | 2008-07-01 | 2021-05-25 | Curemark, Llc | Methods and compositions for the treatment of symptoms of neurological and mental health disorders |
| US10776453B2 (en) * | 2008-08-04 | 2020-09-15 | Galenagen, Llc | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain |
| US20100092447A1 (en) * | 2008-10-03 | 2010-04-15 | Fallon Joan M | Methods and compositions for the treatment of symptoms of prion diseases |
| KR20170005191A (ko) | 2009-01-06 | 2017-01-11 | 큐어론 엘엘씨 | 이. 콜라이에 의한 구강 감염의 치료 또는 예방을 위한 조성물 및 방법 |
| WO2010080830A1 (en) | 2009-01-06 | 2010-07-15 | Curemark Llc | Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces |
| US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
| EP2485744A4 (de) * | 2009-10-09 | 2014-01-22 | Prothera Inc | Zusammensetzungen und verfahren mit pediokokken zur reduzierung mindestens eines symptoms für autismusspektrumserkrankungen bei einem patienten mit diagnostizierter autismusspektrumserkrankung |
| US9511125B2 (en) | 2009-10-21 | 2016-12-06 | Curemark Llc | Methods and compositions for the treatment of influenza |
| EP2552200B1 (de) * | 2010-03-31 | 2015-10-14 | Abela Pharmaceuticals, Inc. | Dimethylsulfoxid (dmso-)formulierungen zur behandlung von autismus |
| US9931365B2 (en) | 2010-09-28 | 2018-04-03 | Lisa Geng | Methods for treating neurological disorders using nutrient compositions |
| WO2012050895A1 (en) | 2010-09-28 | 2012-04-19 | Lisa Geng | Methods for treating neurological disorders using nutrient compositions |
| EP2701733B1 (de) | 2011-04-21 | 2019-04-03 | Curemark, LLC | Verbindungen zur behandlung neuropsychiatrischer störungen |
| US9442092B2 (en) | 2011-06-20 | 2016-09-13 | Kerry Lane | Methods for treatment of autism |
| US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
| AU2018250823A1 (en) | 2017-04-10 | 2019-10-17 | Curemark, Llc | Compositions for treating addiction |
| US11318190B2 (en) * | 2017-05-05 | 2022-05-03 | United States Government As Represented By The Department Of Veterans Affairs | Methods and compositions for treating liver disease |
| CN109908120B (zh) * | 2019-04-22 | 2022-04-19 | 井冈山大学 | 一种狭顶鳞毛蕨有效成分、提取方法及其应用 |
| US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3833722A (en) | 1971-03-16 | 1974-09-03 | D Graybill | Method for controlling allergies |
| JPS5029005B2 (de) * | 1972-05-08 | 1975-09-19 | ||
| US3987014A (en) | 1974-01-10 | 1976-10-19 | Becton, Dickinson And Company | Secretin intermediates and derivatives |
| DE2615229C2 (de) | 1976-04-08 | 1984-05-24 | Hoechst Ag, 6230 Frankfurt | Verfahren zur Herstellung und Reinigung von Sekretin |
| US4086220A (en) | 1976-08-09 | 1978-04-25 | G. D. Searle & Co. | Fragments of secretin |
| EP0021184B1 (de) | 1979-06-13 | 1984-02-08 | Hoechst Aktiengesellschaft | Sekretinpräparate mit verstärkter und protrahierter Wirkung, Verfahren zu ihrer Herstellung sowie Dihydroxybenzoyl-L-tyrosin |
| NZ196349A (en) | 1980-03-07 | 1984-08-24 | Interx Research Corp | Enhancement of absorption rate of orally administered polar bioactive agents |
| JPS58140024A (ja) | 1982-02-15 | 1983-08-19 | Eisai Co Ltd | セクレチンの精製方法 |
| DE3328793A1 (de) | 1983-08-10 | 1985-02-28 | Hoechst Ag, 6230 Frankfurt | Herstellung von sekretin |
| SE454513B (sv) | 1985-03-11 | 1988-05-09 | Kabigen Ab | Humant sekretin samt kompositioner innehallande detta |
| JPS61277618A (ja) | 1985-06-04 | 1986-12-08 | Suntory Ltd | 自閉症治療剤 |
| US5008251A (en) | 1986-03-27 | 1991-04-16 | The Regents Of The University Of California | Method of treating autism |
| US4994467A (en) | 1989-05-31 | 1991-02-19 | Zimmerman Andrew W | Treating autism and other developmental disorders in children with NMDA receptor antagonists |
| US5094837A (en) | 1990-01-22 | 1992-03-10 | Wayne State University | Method for use of magnetic resonance imaging to image pancreas using secretin |
| US5225407A (en) | 1990-02-22 | 1993-07-06 | Glaxo Group Limited | 5-HT3 receptor antagonists for the treatment of autism |
| US5380872A (en) * | 1992-07-14 | 1995-01-10 | Glaxo Inc. | Modulators of cholecystokinin |
| JPH08509465A (ja) | 1993-01-29 | 1996-10-08 | マイリス メディカル コーポレーション | ホルモンの肺内送達 |
| US5527825A (en) | 1994-04-06 | 1996-06-18 | University Of Arkansas | Method of treating schizophrenia, tourette's syndrome, mania, autism, and obsessive compulsive disorder with inhibitors of brain nitric oxide synthase |
| US5560910A (en) * | 1994-08-26 | 1996-10-01 | Crandall; Wilson T. | Topical anti-inflammatory composition and method |
| GB9417524D0 (en) | 1994-08-31 | 1994-10-19 | Cortecs Ltd | Pharmaceutical compositions |
| US5686311A (en) | 1995-06-23 | 1997-11-11 | The Children's Mercy Hospital | Diagnosis of autism and treatment therefor |
| US6020310A (en) * | 1997-05-19 | 2000-02-01 | Repligen Corporation | Method for assisting in differential diagnosis and treatment of autistic syndromes |
| US6197746B1 (en) * | 1998-05-19 | 2001-03-06 | Repligen Corporation | Method of using secretin for treating autism |
| EP1012249A4 (de) | 1997-09-11 | 2002-09-25 | Univ California | Gegen das positive ende gerichteter microtubuli-motor zur chromosomalen kongression |
-
1999
- 1999-01-13 US US09/229,208 patent/US6197746B1/en not_active Expired - Fee Related
- 1999-06-09 DE DE69930739T patent/DE69930739D1/de not_active Expired - Lifetime
- 1999-06-09 JP JP2000553127A patent/JP2002517467A/ja not_active Withdrawn
- 1999-06-09 EP EP99927416A patent/EP1085901B1/de not_active Expired - Lifetime
- 1999-06-09 AU AU44322/99A patent/AU772911B2/en not_active Ceased
- 1999-06-09 WO PCT/US1999/013061 patent/WO1999064059A2/en not_active Ceased
- 1999-06-09 CA CA002333657A patent/CA2333657A1/en not_active Abandoned
- 1999-06-09 AT AT99927416T patent/ATE322283T1/de not_active IP Right Cessation
-
2001
- 2001-03-05 US US09/800,431 patent/US6790825B2/en not_active Expired - Fee Related
-
2003
- 2003-08-08 US US10/637,250 patent/US20050249714A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU4432299A (en) | 1999-12-30 |
| CA2333657A1 (en) | 1999-12-16 |
| US6790825B2 (en) | 2004-09-14 |
| WO1999064059A2 (en) | 1999-12-16 |
| WO1999064059A3 (en) | 2000-03-02 |
| US6197746B1 (en) | 2001-03-06 |
| EP1085901A2 (de) | 2001-03-28 |
| US20050249714A1 (en) | 2005-11-10 |
| JP2002517467A (ja) | 2002-06-18 |
| EP1085901B1 (de) | 2006-04-05 |
| AU772911B2 (en) | 2004-05-13 |
| DE69930739D1 (de) | 2006-05-18 |
| US20010049353A1 (en) | 2001-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE322283T1 (de) | Transdermale verwendung von sekretin zur behandlung von autismus | |
| DE69815122D1 (de) | Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen | |
| ATE204178T1 (de) | Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin | |
| ATE219363T1 (de) | Lösliche prodrugs von paclitaxel | |
| ATE185268T1 (de) | Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin | |
| NO20053077L (no) | Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer. | |
| BR9813373A (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente | |
| DE60239612D1 (de) | Monodisperse mischungen und verfahren zur behandlung von diabetes | |
| RU2000130209A (ru) | Новое применение | |
| ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| DE69636343D1 (de) | Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen | |
| ATE410506T1 (de) | Behandlung der pompeschen krankheit | |
| RU94027680A (ru) | Паращитовидный гормон и ралоксифон для увеличения массы кости, фармацевтический состав и способ увеличения костной массы | |
| MD960307A (ro) | Compoziţii farmaceutice cu conţinut de acid hialuronic, utilizarea compoziţiilor pentru tratamentul bolilor pielii, metodă de tratament al bolilor pielii | |
| ATE154758T1 (de) | Levobupivacain nützlich zur behandlung von chronischen schmerzen | |
| DE69914084D1 (de) | Phenylacetylglutamin, phenylacetylisoglutamin, und/oder phenylacetat zur behandlung von neoplastischen erkrankungen | |
| ATE93138T1 (de) | Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie. | |
| DE58901002D1 (de) | Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken. | |
| BR9813318A (pt) | Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário | |
| IL192287A0 (en) | Pharmaceutical compositions and methods for use | |
| DE69426471D1 (de) | Verwendung von Sulodexid und von Arzneimitteln, die dieses enthalten, zur Behandlung der diabetischen Nephropathie | |
| BR9908190A (pt) | Processos para tratar a dor especìfica de fêmea em um paciente fêmea, e para tratar a dor crÈnica em um paciente | |
| PT1231908E (pt) | Composicao farmaceutica compreendendo um composto dador de no e sua utilizacao em terapia | |
| RU95100951A (ru) | Способ лечения мужского бесплодия | |
| AR005724A1 (es) | Derivados de ureido biologicamente activos utiles en el tratamiento de esclerosis multiple |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |